FOXD3 and cancer: ASOs and RNAi allow for the specific degradation or blockage of lncRNAs, providing evidence from human preclinical models of knockdown of FOXD3-AS1 or MIAT that led to the suppression of aggressive cancer phenotypes and modified key signaling pathways [19,75].